Studies have shown that while CBD reduces pain sensation in animals, its ability to do so in humans is limited by low bioavailability, the extent to which the drug successfully reaches its site of action. Now, new research suggests this obstacle may be overcome by a novel CBD analog known as KLS-13019.
